Three Biotech Stocks Working On CAR-T Immunotherapy You Ought To See
Source: Juno Therapeutics.
Last week, Celgene Corp. (NASDAQ:CELG) shocked biotech investors when it agreed to pay $1 billion for $850 million worth of Juno Therapeutics‘ (NASDAQ:JUNO) stock and a handful of licensing rights, leaving Celgene with a 10% stake in the smaller company.
Juno Therapeutics is at the forefront of developing chimeric antigen receptor, or CAR, T-cell therapies, and the deal secures Celgene’s access to next-generation therapies. However, Juno Therapeutics isn’t the only company exploring the potential to reengineer T cells to help patients’ immune systems better find and demolish cancer cells; Kite Pharma (NASDAQ:KITE) and Ziopharm Oncology (NASDAQ:ZIOP) are also exploring the possibility.
Locking up a leader
Juno Therapeutics’ most advanced therapy is JCAR015, a CAR-T treatment for use in adults with acute lymphoblastic leukemia. In a petite, early-stage trial, 89% of twenty seven evaluable patients treated with JCAR015 experienced accomplish remission.
Those results were likely a major reason why Celgene inked its recently-announced deal, which includes that big equity investment, as well as an up-front cash payment to lock up options to foreign rights to Juno Therapeutics’ CAR-T program.
Source: Juno Therapeutics.
Attempting to outpace it
Kite Pharma is developing KTE-C19 as a therapy for the treatment of aggressive non-Hodgkin lymphoma that voices the CD19 antigen, the same protein that JCAR015 targets.
Last August, Kite Pharma reported that eight of thirteen patients with B-cell cancer receiving KTE-C19 experienced accomplish remission and that another four patients underwent partial remission.
That’s a solid demonstrating for this early-stage program, and while Juno Therapeutics’ fresh cash gives it plasticity, Kite Pharma’s coffers aren’t too shabby either. Exiting the very first quarter, Kite Pharma’s balance sheet boasted $428.Five million in cash and no debt.
Source: Kite Pharma.
Ziopharm Oncology’s treatment differs from Juno Therapeutics and Kite Pharma based on its concentrate on reengineering T cells that are more effective and pose lower risk to healthy cells. To do that, Ziopharm is employing Intrexon Corp.’s RheoSwitch technology, which can switch on and off T-cell activity.
The most advanced drug in Ziopharm Oncology’s pipeline is Ad-RTS-IL-12, which is being studied in phase two trials for use in breast cancer patients. Other drugs in development include CAR-T therapies for B-cell malignancies, such as those being targeted by Juno Therapeutics and Kite Pharma. Overall, Ziopharm is guiding to have five CAR therapies in human trials by year-end.
Source: Ziopharm Oncology.
Should you buy these stocks?
There’s no assure any of them will duplicate their early-stage clinical successes in larger, later-stage trials necessary for approval. Even if they do, we’re still years from having a product from one of these companies on the market. For example, Celgene believes the very first therapy from its Juno Therapeutics collaboration will come no earlier than 2020.
Albeit all three of these companies are risky, Juno Therapeutics might be the best bet. Its collaboration with Celgene means it has the best balance sheet of the trio and a well-heeled and massively successful potential marketing playmate.
Regardless, the fact that CAR-T immunotherapies could revolutionize patient treatment by improving outcomes and limiting toxicity tied to chemotherapy makes all three companies worth watching.
Three Biotech Stocks Working On CAR-T Immunotherapy You Ought To See – The Motley Loser
Three Biotech Stocks Working On CAR-T Immunotherapy You Ought To Witness
Source: Juno Therapeutics.
Last week, Celgene Corp. (NASDAQ:CELG) shocked biotech investors when it agreed to pay $1 billion for $850 million worth of Juno Therapeutics‘ (NASDAQ:JUNO) stock and a handful of licensing rights, leaving Celgene with a 10% stake in the smaller company.
Juno Therapeutics is at the forefront of developing chimeric antigen receptor, or CAR, T-cell therapies, and the deal secures Celgene’s access to next-generation therapies. However, Juno Therapeutics isn’t the only company exploring the potential to reengineer T cells to help patients’ immune systems better find and demolish cancer cells; Kite Pharma (NASDAQ:KITE) and Ziopharm Oncology (NASDAQ:ZIOP) are also exploring the possibility.
Locking up a leader
Juno Therapeutics’ most advanced therapy is JCAR015, a CAR-T treatment for use in adults with acute lymphoblastic leukemia. In a puny, early-stage trial, 89% of twenty seven evaluable patients treated with JCAR015 experienced finish remission.
Those results were likely a major reason why Celgene inked its recently-announced deal, which includes that big equity investment, as well as an up-front cash payment to lock up options to foreign rights to Juno Therapeutics’ CAR-T program.
Source: Juno Therapeutics.
Attempting to outpace it
Kite Pharma is developing KTE-C19 as a therapy for the treatment of aggressive non-Hodgkin lymphoma that voices the CD19 antigen, the same protein that JCAR015 targets.
Last August, Kite Pharma reported that eight of thirteen patients with B-cell cancer receiving KTE-C19 experienced accomplish remission and that another four patients underwent partial remission.
That’s a solid demonstrating for this early-stage program, and while Juno Therapeutics’ fresh cash gives it plasticity, Kite Pharma’s coffers aren’t too shabby either. Exiting the very first quarter, Kite Pharma’s balance sheet boasted $428.Five million in cash and no debt.
Source: Kite Pharma.
Ziopharm Oncology’s treatment differs from Juno Therapeutics and Kite Pharma based on its concentrate on reengineering T cells that are more effective and pose lower risk to healthy cells. To do that, Ziopharm is employing Intrexon Corp.’s RheoSwitch technology, which can switch on and off T-cell activity.
The most advanced drug in Ziopharm Oncology’s pipeline is Ad-RTS-IL-12, which is being studied in phase two trials for use in breast cancer patients. Other drugs in development include CAR-T therapies for B-cell malignancies, such as those being targeted by Juno Therapeutics and Kite Pharma. Overall, Ziopharm is guiding to have five CAR therapies in human trials by year-end.
Source: Ziopharm Oncology.
Should you buy these stocks?
There’s no ensure any of them will duplicate their early-stage clinical successes in larger, later-stage trials necessary for approval. Even if they do, we’re still years from having a product from one of these companies on the market. For example, Celgene believes the very first therapy from its Juno Therapeutics collaboration will come no earlier than 2020.
Albeit all three of these companies are risky, Juno Therapeutics might be the best bet. Its collaboration with Celgene means it has the best balance sheet of the trio and a well-heeled and massively successful potential marketing fucking partner.
Regardless, the fact that CAR-T immunotherapies could revolutionize patient treatment by improving outcomes and limiting toxicity tied to chemotherapy makes all three companies worth watching.
Trio Biotech Stocks Working On CAR-T Immunotherapy You Ought To Observe – The Motley Loser
Three Biotech Stocks Working On CAR-T Immunotherapy You Ought To Witness
Source: Juno Therapeutics.
Last week, Celgene Corp. (NASDAQ:CELG) shocked biotech investors when it agreed to pay $1 billion for $850 million worth of Juno Therapeutics‘ (NASDAQ:JUNO) stock and a handful of licensing rights, leaving Celgene with a 10% stake in the smaller company.
Juno Therapeutics is at the forefront of developing chimeric antigen receptor, or CAR, T-cell therapies, and the deal secures Celgene’s access to next-generation therapies. However, Juno Therapeutics isn’t the only company exploring the potential to reengineer T cells to help patients’ immune systems better find and demolish cancer cells; Kite Pharma (NASDAQ:KITE) and Ziopharm Oncology (NASDAQ:ZIOP) are also exploring the possibility.
Locking up a leader
Juno Therapeutics’ most advanced therapy is JCAR015, a CAR-T treatment for use in adults with acute lymphoblastic leukemia. In a petite, early-stage trial, 89% of twenty seven evaluable patients treated with JCAR015 experienced accomplish remission.
Those results were likely a major reason why Celgene inked its recently-announced deal, which includes that big equity investment, as well as an up-front cash payment to lock up options to foreign rights to Juno Therapeutics’ CAR-T program.
Source: Juno Therapeutics.
Attempting to outpace it
Kite Pharma is developing KTE-C19 as a therapy for the treatment of aggressive non-Hodgkin lymphoma that voices the CD19 antigen, the same protein that JCAR015 targets.
Last August, Kite Pharma reported that eight of thirteen patients with B-cell cancer receiving KTE-C19 experienced finish remission and that another four patients underwent partial remission.
That’s a solid demonstrating for this early-stage program, and while Juno Therapeutics’ fresh cash gives it plasticity, Kite Pharma’s coffers aren’t too shabby either. Exiting the very first quarter, Kite Pharma’s balance sheet boasted $428.Five million in cash and no debt.
Source: Kite Pharma.
Ziopharm Oncology’s treatment differs from Juno Therapeutics and Kite Pharma based on its concentrate on reengineering T cells that are more effective and pose lower risk to healthy cells. To do that, Ziopharm is employing Intrexon Corp.’s RheoSwitch technology, which can switch on and off T-cell activity.
The most advanced drug in Ziopharm Oncology’s pipeline is Ad-RTS-IL-12, which is being studied in phase two trials for use in breast cancer patients. Other drugs in development include CAR-T therapies for B-cell malignancies, such as those being targeted by Juno Therapeutics and Kite Pharma. Overall, Ziopharm is guiding to have five CAR therapies in human trials by year-end.
Source: Ziopharm Oncology.
Should you buy these stocks?
There’s no ensure any of them will duplicate their early-stage clinical successes in larger, later-stage trials necessary for approval. Even if they do, we’re still years from having a product from one of these companies on the market. For example, Celgene believes the very first therapy from its Juno Therapeutics collaboration will come no earlier than 2020.
Albeit all three of these companies are risky, Juno Therapeutics might be the best bet. Its collaboration with Celgene means it has the best balance sheet of the trio and a well-heeled and massively successful potential marketing fucking partner.
Regardless, the fact that CAR-T immunotherapies could revolutionize patient treatment by improving outcomes and limiting toxicity tied to chemotherapy makes all three companies worth watching.
Trio Biotech Stocks Working On CAR-T Immunotherapy You Ought To Observe – The Motley Loser
Trio Biotech Stocks Working On CAR-T Immunotherapy You Ought To Observe
Source: Juno Therapeutics.
Last week, Celgene Corp. (NASDAQ:CELG) shocked biotech investors when it agreed to pay $1 billion for $850 million worth of Juno Therapeutics‘ (NASDAQ:JUNO) stock and a handful of licensing rights, leaving Celgene with a 10% stake in the smaller company.
Juno Therapeutics is at the forefront of developing chimeric antigen receptor, or CAR, T-cell therapies, and the deal secures Celgene’s access to next-generation therapies. However, Juno Therapeutics isn’t the only company exploring the potential to reengineer T cells to help patients’ immune systems better find and demolish cancer cells; Kite Pharma (NASDAQ:KITE) and Ziopharm Oncology (NASDAQ:ZIOP) are also exploring the possibility.
Locking up a leader
Juno Therapeutics’ most advanced therapy is JCAR015, a CAR-T treatment for use in adults with acute lymphoblastic leukemia. In a puny, early-stage trial, 89% of twenty seven evaluable patients treated with JCAR015 experienced accomplish remission.
Those results were likely a major reason why Celgene inked its recently-announced deal, which includes that big equity investment, as well as an up-front cash payment to lock up options to foreign rights to Juno Therapeutics’ CAR-T program.
Source: Juno Therapeutics.
Attempting to outpace it
Kite Pharma is developing KTE-C19 as a therapy for the treatment of aggressive non-Hodgkin lymphoma that voices the CD19 antigen, the same protein that JCAR015 targets.
Last August, Kite Pharma reported that eight of thirteen patients with B-cell cancer receiving KTE-C19 experienced finish remission and that another four patients underwent partial remission.
That’s a solid demonstrating for this early-stage program, and while Juno Therapeutics’ fresh cash gives it plasticity, Kite Pharma’s coffers aren’t too shabby either. Exiting the very first quarter, Kite Pharma’s balance sheet boasted $428.Five million in cash and no debt.
Source: Kite Pharma.
Ziopharm Oncology’s treatment differs from Juno Therapeutics and Kite Pharma based on its concentrate on reengineering T cells that are more effective and pose lower risk to healthy cells. To do that, Ziopharm is employing Intrexon Corp.’s RheoSwitch technology, which can switch on and off T-cell activity.
The most advanced drug in Ziopharm Oncology’s pipeline is Ad-RTS-IL-12, which is being studied in phase two trials for use in breast cancer patients. Other drugs in development include CAR-T therapies for B-cell malignancies, such as those being targeted by Juno Therapeutics and Kite Pharma. Overall, Ziopharm is guiding to have five CAR therapies in human trials by year-end.
Source: Ziopharm Oncology.
Should you buy these stocks?
There’s no ensure any of them will duplicate their early-stage clinical successes in larger, later-stage trials necessary for approval. Even if they do, we’re still years from having a product from one of these companies on the market. For example, Celgene believes the very first therapy from its Juno Therapeutics collaboration will come no earlier than 2020.
Albeit all three of these companies are risky, Juno Therapeutics might be the best bet. Its collaboration with Celgene means it has the best balance sheet of the trio and a well-heeled and massively successful potential marketing fucking partner.
Regardless, the fact that CAR-T immunotherapies could revolutionize patient treatment by improving outcomes and limiting toxicity tied to chemotherapy makes all three companies worth watching.